Bradley Tajuana, Davis Mark, Martin Julie, Woodward Susan
From Georgia Cancer Specialists, Atlanta, Georgia.
Texas Oncology, Fort Worth, Texas.
J Adv Pract Oncol. 2024 Nov 5:1-16. doi: 10.6004/jadpro.2024.15.8.21.
Follicular lymphoma (FL) is a disease often characterized by chronic and successive relapses after first-line chemoimmunotherapy. Although chemoimmunotherapy and combination therapy, such as lenalidomide with rituximab, are well established in the treatment sequence of FL, there is a need to streamline treatment options and determine placement of novel agents, such as chimeric antigen receptor T-cell therapy, an enhancer of zeste homolog 2 inhibitor, or a phosphoinositide 3 kinase inhibitor, into the treatment landscape. As such, the purpose of this review is to compare the safety profiles of approved agents in subsequent lines of therapy for relapsed or refractory FL and to assess how the management of adverse events may impact treatment choice.
滤泡性淋巴瘤（FL）是一种疾病，其特征通常是一线化疗免疫治疗后出现慢性且连续的复发。尽管化疗免疫治疗以及联合治疗，如来那度胺与利妥昔单抗的联合治疗，在FL的治疗序列中已得到充分确立，但仍需要简化治疗方案，并确定新型药物，如嵌合抗原受体T细胞疗法、zeste同源物2抑制剂或磷酸肌醇3激酶抑制剂，在治疗格局中的位置。因此，本综述的目的是比较已获批药物在复发或难治性FL后续治疗线中的安全性概况，并评估不良事件的管理如何影响治疗选择。
